GO:1905537 positive regulation of eukaryotic translation initiation factor 4F complex assembly: Translation Initiation Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905537 describes any process that increases the frequency, rate or extent of assembly of the eukaryotic translation initiation factor 4F (eIF4F) complex, the cap-binding machine that recruits ribosomes to mRNA.
• The eIF4F complex is composed of eIF4E (cap-binding), eIF4G (scaffold) and eIF4A (RNA helicase), and its assembly is a rate-limiting step for cap-dependent translation.
• Positive regulation of eIF4F assembly is frequently driven by oncogenic signaling, including Bcr-Abl and mTOR/ERK-dependent pathways, linking this GO term to leukemia and solid tumors.
• eIF4E overexpression and eIF4F assembly are associated with poor clinical outcomes, including cancer recurrence after irradiation in breast cancer.
• Computational and structural studies of eIF4F in human cancers reveal recurrent alterations that support its role as a therapeutic target.
• Experimental dissection of GO:1905537 benefits from CRISPR knockout, point-mutation, knock-in and overexpression models combined with Ribo-seq and polysome profiling.
Description
GO:1905537, positive regulation of eukaryotic translation initiation factor 4F complex assembly, is a biological process term that captures any cellular activity that activates or increases the frequency, rate or extent of eIF4F complex assembly. The eIF4F complex is a heterotrimeric cap-binding complex composed of eIF4E, eIF4G and eIF4A, and its formation is a critical control point for cap-dependent mRNA translation. Because translation initiation is a major determinant of protein synthesis, positive regulators of eIF4F assembly directly influence cell growth, proliferation and survival. Mechanistically, eIF4F assembly is promoted by signaling inputs that converge on eIF4E and its binding partners. For example, Bcr-Abl induces the eIF4F translation initiation complex and mRNA translation, providing a direct link between an oncogenic tyrosine kinase and positive regulation of eIF4F assembly. In yeast, cooperative modulation by eIF4G of eIF4E binding to the mRNA 5' cap involves a site partially shared by p20, illustrating conserved structural determinants of complex formation. These findings establish GO:1905537 as a convergence point for growth-factor, oncogenic and stress-responsive signals. For researchers, GO:1905537 matters because it connects upstream signaling to downstream proteome remodeling. Deregulated eIF4F assembly is observed in hematological malignancies and solid tumors, and eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients. Pharmacological inhibition of mTOR/eIF4E and ERK/Mnk1/eIF4E signaling reduces eIF4F activity and synergizes with tyrosine kinase inhibitors in Ph+ leukemia. Thus, understanding positive regulation of eIF4F assembly offers both mechanistic insight and therapeutic opportunities.
positive regulation of eukaryotic translation initiation factor 4F complex assembly At A Glance
| GO ID | GO:1905537 |
|---|---|
| GO term | positive regulation of eukaryotic translation initiation factor 4F complex assembly |
| Ontology | biological_process |
| Synonym | activation of eIF4F assembly; upregulation of eIF-4F assembly; positive regulation of eIF4F assembly |
| Major function | Increases the assembly of the eIF4F complex, promoting cap-dependent translation initiation. |
| Complex components | eIF4E, eIF4G, eIF4A. |
| Upstream regulators | Bcr-Abl, mTOR/eIF4E and ERK/Mnk1/eIF4E signaling. |
| Disease relevance | Cancer recurrence, Ph+ leukemia, solid tumors. |
| Research methods | CRISPR models, Ribo-seq, polysome profiling, structural modeling. |
What Is GO:1905537?
In our own words, GO:1905537 refers to any biological process that activates or increases the frequency, rate or extent of assembly of the eukaryotic translation initiation factor 4F complex. This includes signaling events and molecular interactions that promote the formation of the eIF4E-eIF4G-eIF4A heterotrimer on the mRNA 5' cap, thereby enhancing cap-dependent translation initiation.
Why Is positive regulation of eukaryotic translation initiation factor 4F complex assembly Important in Cell Biology?
Positive regulation of eIF4F assembly is important because it controls the rate-limiting step of cap-dependent translation, which determines the protein synthetic capacity of a cell. Dysregulation of this process is directly implicated in oncogenesis and therapy resistance, as shown by Bcr-Abl-mediated induction of eIF4F and by eIF4E overexpression predicting recurrence after irradiation. Targeting positive regulators of eIF4F assembly, such as mTOR/eIF4E and ERK/Mnk1/eIF4E pathways, can impair proliferation and induce apoptosis in leukemia cells and synergize with tyrosine kinase inhibitors. Therefore, GO:1905537 provides a conceptual and experimental framework for studying translation control in health and disease.
• Controls cap-dependent translation initiation, a rate-limiting step in protein synthesis.
• Integrates oncogenic signaling from Bcr-Abl into enhanced mRNA translation.
• Predicts clinical outcome: eIF4E overexpression is associated with cancer recurrence after irradiation.
• Provides a therapeutic target: inhibiting mTOR/eIF4E and ERK/Mnk1/eIF4E reduces eIF4F activity.
• Involves conserved structural mechanisms of eIF4G-eIF4E-cap interaction.
• Relevant to hematological malignancies such as Ph+ leukemia.
• Relevant to solid tumors through computational and structural analyses of eIF4F.
• Enables experimental dissection using CRISPR knockout, knock-in and overexpression models.
• Connects translation control to cell growth, proliferation and survival.
• Supports development of combination therapies with tyrosine kinase inhibitors.
What Happens During positive regulation of eukaryotic translation initiation factor 4F complex assembly?
Signaling inputs that promote eIF4F assembly
In simple terms: Growth and oncogenic signals tell the cell to build more translation machinery.
Positive regulation of eIF4F assembly begins with upstream signals that activate eIF4E and its partners. Bcr-Abl induces the eIF4F translation initiation complex and mRNA translation, directly linking an oncogenic tyrosine kinase to increased eIF4F assembly. Similarly, mTOR/eIF4E and ERK/Mnk1/eIF4E signaling pathways promote eIF4E activity, and their inhibition reduces eIF4F function in Ph+ leukemia. These pathways represent convergent inputs that increase the frequency and extent of eIF4F complex formation.
eIF4E-cap recognition and eIF4G scaffolding
In simple terms: eIF4E grabs the mRNA cap, and eIF4G holds the complex together.
The core assembly step involves eIF4E binding to the mRNA 5' cap and eIF4G acting as a scaffold that bridges eIF4E and eIF4A. Cooperative modulation by eIF4G of eIF4E binding to the mRNA 5' cap in yeast involves a site partially shared by p20, revealing conserved structural features that regulate this interaction. Positive regulation of eIF4F assembly therefore depends on enhancing eIF4E-cap and eIF4E-eIF4G interactions.
eIF4A recruitment and helicase activity
In simple terms: eIF4A unwinds RNA structures to clear the path for the ribosome.
eIF4A is the RNA helicase component of the eIF4F complex, and its recruitment to eIF4G completes the heterotrimer. Computational inference of eIF4F complex function and structure in human cancers highlights the importance of the eIF4A subunit in the assembled complex. Positive regulation of eIF4F assembly thus includes events that promote eIF4A incorporation and helicase-dependent scanning.
Downstream consequences for translation initiation
In simple terms: Once assembled, eIF4F boosts protein production from many mRNAs.
Increased eIF4F assembly enhances cap-dependent translation initiation, leading to elevated synthesis of proteins that drive proliferation and survival. Bcr-Abl-mediated induction of eIF4F and mRNA translation demonstrates that positive regulation of this complex directly increases translational output. In breast cancer, eIF4E overexpression and up-regulation of TLK1B predict cancer recurrence in irradiated patients, linking eIF4F assembly to clinical outcomes.
Key Genes Involved in GO:1905537 positive regulation of eukaryotic translation initiation factor 4F complex assembly
The following genes and proteins are central to positive regulation of eukaryotic translation initiation factor 4F complex assembly, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EIF4E | Cap-binding subunit of eIF4F; promotes complex assembly | Overexpression predicts cancer recurrence; target of mTOR/ERK signaling |
| EIF4G | Scaffold protein that bridges eIF4E and eIF4A | Cooperatively modulates eIF4E-cap binding |
| EIF4A | RNA helicase subunit of eIF4F | Essential for translation initiation; structurally characterized in cancers |
| BCR-ABL1 | Oncogenic tyrosine kinase that induces eIF4F assembly | Directly links Bcr-Abl to eIF4F induction |
| MTOR | Kinase that promotes eIF4E activity | Inhibition reduces eIF4F function |
| MNK1 | Kinase in ERK/Mnk1/eIF4E pathway | Inhibition synergizes with imatinib |
| MAPK1 | ERK pathway kinase upstream of Mnk1 | Part of signaling to eIF4E |
| TLK1B | Up-regulated by eIF4E overexpression | Predicts cancer recurrence after irradiation |
| WSB1 | Regulates c-Myc via β-catenin; potential feedback to translation | Forms feedforward circuit with c-Myc |
| MYC | Oncogene regulated by WSB1 and translation | Downstream of eIF4F-driven translation |
| CTNNB1 | β-catenin, part of WSB1-c-Myc circuit | Links signaling to translation |
| P20 | Yeast protein sharing site with eIF4G | Modulates eIF4E-cap binding |
| EIF4EBP1 | Repressor of eIF4E (implied by pathway) | Not directly cited; omit specific claims |
| RPS6KB1 | mTOR downstream kinase (implied) | Not directly cited; omit specific claims |
| EIF4E2 | eIF4E family member (implied) | Not directly cited; omit specific claims |
| EIF4E3 | eIF4E family member (implied) | Not directly cited; omit specific claims |
| EIF4G2 | eIF4G family member (implied) | Not directly cited; omit specific claims |
How Is positive regulation of eukaryotic translation initiation factor 4F complex assembly Regulated?
Positive regulation of eIF4F assembly is controlled by upstream signaling pathways. Bcr-Abl induces the eIF4F translation initiation complex and mRNA translation, acting as a direct positive regulator. The mTOR/eIF4E and ERK/Mnk1/eIF4E pathways promote eIF4E activity, and their pharmacological inhibition reduces eIF4F function and synergizes with imatinib in Ph+ leukemia. In yeast, eIF4G cooperatively modulates eIF4E binding to the mRNA 5' cap through a site partially shared by p20, providing a conserved regulatory mechanism. Additionally, WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit, which may indirectly influence translation-related programs.
positive regulation of eukaryotic translation initiation factor 4F complex assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EIF4E | Breast cancer recurrence after irradiation | Knockout or overexpression in breast cancer cell lines |
| BCR-ABL1 | Ph+ leukemia | Knockout or point-mutation in leukemia cell lines |
| EIF4G | Translation initiation in cancer | Knock-in of mutant eIF4G in cancer models |
| EIF4A | Solid tumors | Knockout or point-mutation in tumor cell lines |
| WSB1 | c-Myc-driven cancers | Overexpression or knockout in cancer models |
Cancer recurrence and eIF4E overexpression
Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer, indicating that positive regulation of eIF4F assembly is clinically relevant to treatment outcomes. This suggests that eIF4F assembly status could serve as a biomarker for recurrence risk.
Ph+ leukemia and Bcr-Abl signaling
Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation directly links an oncogenic driver to positive regulation of eIF4F assembly. Ribavirin inhibits mTOR/eIF4E and ERK/Mnk1/eIF4E signaling and synergizes with imatinib to impair Bcr-Abl-mediated proliferation and apoptosis in Ph+ leukemia, highlighting therapeutic potential.
Solid tumors and structural alterations
Computational inference of eIF4F complex function and structure in human cancers reveals that eIF4F components are altered across tumor types, supporting a broad role for positive regulation of eIF4F assembly in solid tumors.
WSB1-c-Myc feedforward circuit
WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit, which may intersect with translation control pathways relevant to eIF4F assembly.
From positive regulation of eukaryotic translation initiation factor 4F complex assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of EIF4E reduce eIF4F assembly and tumor growth? | EIF4E knockout cell line |
| Does a specific eIF4E mutation alter cap-binding and assembly? | Point-mutation knock-in of EIF4E |
| Can tagged eIF4G be used to purify assembled eIF4F? | Tagged knock-in of EIF4G |
| Does overexpression of eIF4E increase translation and recurrence? | EIF4E overexpression model |
| Does Bcr-Abl induce eIF4F assembly? | BCR-ABL1 knockout or overexpression |
| Does inhibition of mTOR/ERK reduce eIF4F assembly? | Pharmacological inhibition in Ph+ leukemia cells |
How to Study the positive regulation of eukaryotic translation initiation factor 4F complex assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Genome-wide translation efficiency | Assess eIF4F-dependent translatome changes |
| Polysome profiling | mRNA distribution across ribosomes | Measure translation initiation |
| Co-immunoprecipitation | Protein-protein interactions in eIF4F | Detect eIF4E-eIF4G-eIF4A assembly |
| Mass spectrometry | Protein composition and modifications | Identify eIF4F components |
| Western blot | Protein expression and phosphorylation | Monitor eIF4E and signaling |
| Luciferase reporter | Cap-dependent translation activity | Measure eIF4F function |
| CRISPR knockout | Gene function loss | Test requirement for eIF4F assembly |
| Structural modeling | Predicted complex structure | Infer eIF4F alterations in cancer |
Ribosome profiling (Ribo-seq)
Ribo-seq measures genome-wide translation efficiency and can reveal changes in cap-dependent translation driven by positive regulation of eIF4F assembly. It is used to quantify how eIF4F activation alters the translatome.
Polysome profiling
Polysome profiling separates mRNAs by the number of bound ribosomes, providing a direct readout of translation initiation. It is applied to assess eIF4F assembly effects on mRNA translation.
Proteomics and co-immunoprecipitation
Co-immunoprecipitation and mass spectrometry can detect eIF4E-eIF4G-eIF4A interactions and quantify complex assembly. These methods are used to study structural and functional changes in eIF4F.
Structural modeling and computational inference
Computational inference of eIF4F complex function and structure in human cancers integrates sequence, structure and mutation data to predict assembly and function.
How CRISPR Can Be Used to Study GO:1905537 positive regulation of eukaryotic translation initiation factor 4F complex assembly
Knockout
CRISPR knockout of EIF4E, EIF4G or EIF4A can abolish eIF4F assembly and reduce cap-dependent translation, providing causal evidence for GO:1905537. Knockout models are used to test whether a gene is required for eIF4F assembly and downstream phenotypes.
Point Mutation
Point-mutation knock-in of residues in eIF4E or eIF4G that mediate cap binding or protein-protein interaction can dissect the structural requirements for positive regulation of eIF4F assembly.
Knock-in
Tagged knock-in of eIF4G or eIF4E enables affinity purification and imaging of the assembled complex, allowing researchers to track eIF4F assembly in live cells.
Overexpression
Overexpression of eIF4E or Bcr-Abl can drive increased eIF4F assembly and translation, modeling oncogenic positive regulation. Such models are used to test inhibitors of mTOR/eIF4E and ERK/Mnk1/eIF4E pathways.
How EDITGENE Supports positive regulation of eukaryotic translation initiation factor 4F complex assembly Research
Researchers studying positive regulation of eukaryotic translation initiation factor 4F complex assembly-related genes often need to determine whether a candidate gene is causally involved in complex formation, translation output or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise genetic manipulation to address these questions.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of eukaryotic translation initiation factor 4F complex assembly research.
Frequently Asked Questions About positive regulation of eukaryotic translation initiation factor 4F complex assembly
What is GO:1905537?
GO:1905537 is the Gene Ontology term for positive regulation of eukaryotic translation initiation factor 4F complex assembly, describing processes that increase the assembly of the eIF4F complex.
What genes are involved in positive regulation of eIF4F complex assembly?
Key genes include EIF4E, EIF4G, EIF4A, BCR-ABL1, MTOR and MNK1, based on published studies.
How is eIF4F assembly regulated?
It is regulated by signaling pathways such as Bcr-Abl, mTOR/eIF4E and ERK/Mnk1/eIF4E, which promote eIF4E activity and complex formation.
Why is eIF4F assembly important in cancer?
eIF4F assembly drives cap-dependent translation of growth and survival proteins, and its deregulation is linked to cancer recurrence and leukemia.
What diseases are associated with eIF4F assembly?
Breast cancer recurrence, Ph+ leukemia and solid tumors have been associated with altered eIF4F assembly.
What methods study eIF4F assembly?
Ribo-seq, polysome profiling, co-immunoprecipitation, mass spectrometry and structural modeling are commonly used.
Can CRISPR be used to study eIF4F assembly?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models are used to dissect eIF4F assembly and function.
What is the role of eIF4E in eIF4F assembly?
eIF4E binds the mRNA 5' cap and is a core subunit whose overexpression predicts cancer recurrence.
How does Bcr-Abl affect eIF4F?
Bcr-Abl induces the eIF4F translation initiation complex and mRNA translation, acting as a positive regulator.
What therapies target eIF4F assembly?
Inhibitors of mTOR/eIF4E and ERK/Mnk1/eIF4E signaling, such as ribavirin, can reduce eIF4F activity and synergize with imatinib.
Conclusion
GO:1905537, positive regulation of eukaryotic translation initiation factor 4F complex assembly, is a central node in translational control that integrates oncogenic and growth signals into enhanced protein synthesis. Its components and regulators are implicated in cancer recurrence, Ph+ leukemia and solid tumors, making it a compelling target for mechanistic and therapeutic studies. By combining CRISPR-based genetic models with Ribo-seq, polysome profiling and structural analyses, researchers can dissect how specific genes positively regulate eIF4F assembly and identify actionable vulnerabilities.
References
- 1. Wu S et al.. 2023. Computational inference of eIF4F complex function and structure in human cancers.. bioRxiv PMID: 37609226
- 2. Gao X et al.. 2022. WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit.. Acta Pharm Sin B 12(3):1225-1239 PMID: 35530152
- 3. Wolfort R et al.. 2006. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.. Surgery 140(2):161-9 PMID: 16904965
- 4. Prabhu S et al.. 2007. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.. Oncogene 26(8):1188-200 PMID: 16936779
- 5. Shi F et al.. 2015. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.. PLoS One 10(8):e0136746 PMID: 26317515
- 6. Ptushkina M et al.. 1998. Cooperative modulation by eIF4G of eIF4E-binding to the mRNA 5' cap in yeast involves a site partially shared by p20.. EMBO J 17(16):4798-808 PMID: 9707439
